Statera BioPharma Licenses Entolimod to Tivic Health for Innovative ARS Treatment Strategy
- Tivic Health has secured exclusive licensing rights for Entolimod™ from Statera BioPharma to address acute radiation syndrome.
- The partnership aims to enhance both companies’ capabilities and diversify Tivic’s product offerings in therapeutics.
- Statera BioPharma is optimistic about the collaboration, anticipating significant shareholder value and progress toward FDA approval for Entolimod.
Tivic Health's Strategic Acquisition of Entolimod: A Leap into Therapeutics
Tivic Health Systems, Inc. has recently secured worldwide exclusive licensing rights for the Toll-like Receptor 5 (TLR5) agonist Entolimod™ from Statera BioPharma. This significant acquisition aims to address acute radiation syndrome (ARS), a condition that can arise from exposure to high levels of radiation. This move marks a pivotal shift for Tivic as it transitions from its previous direct-to-consumer model toward a more diversified therapeutics-focused approach. With this new direction, Tivic plans to expand its clinical pipeline and explore multiple therapeutic indications for Entolimod and its derivative, Entalasta™.
Entolimod is not a new entrant in the biomedical field; it has undergone extensive research, with over 40 clinical trials and a prior investment of $140 million. The drug possesses promising attributes, including Fast Track and Orphan Drug designations from the FDA specifically for treating ARS. Recent studies have demonstrated that Entolimod can significantly increase survival rates in animal models exposed to lethal radiation levels, showing a remarkable three-fold increase when administered 25 hours post-exposure. Importantly, the drug also offers gastrointestinal protective qualities without notable toxicity, indicating its potential as a safe and effective treatment option.
The market for ARS is projected to reach $5.2 billion by 2024, featuring a steady growth rate of 5% annually until 2031. Statera BioPharma has positioned itself as a leader in this space, and the licensing agreement with Tivic Health is expected to enhance the capabilities of both companies. Jennifer Ernst, CEO of Tivic, highlights that this partnership will not only diversify their product offerings but also aim to provide innovative solutions for radiation-related illnesses. Meanwhile, Michael K. Handley, CEO of Statera, expresses optimism about the collaboration, believing it will yield considerable value for shareholders as they work towards submitting a Biologics License Application (BLA) for Entolimod.
In addition to the acquisition, Tivic's commitment to aligning its TLR5 immunotherapy program with non-invasive vagus nerve stimulation therapies underscores the company's strategic focus on addressing immune and autonomic dysregulation. As Tivic pivots towards a broader therapeutic framework, it positions itself as a competitive player in the biopharmaceutical landscape, particularly in the niche market of radiation trauma therapies.
This collaboration between Tivic Health and Statera BioPharma not only strengthens their market position but also underscores the growing importance of innovative treatments in managing acute health crises. As both companies advance their efforts toward FDA approval for Entolimod, they exemplify the potential for synergistic partnerships in the evolving field of therapeutics.